Can a single shot shield children from chikungunya?

NCT ID NCT06106581

Completed ⭐️ VACCINE ⭐️ Sponsor: Valneva Austria GmbH Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial is testing whether a single injection of an experimental chikungunya vaccine, VLA1553, is safe and triggers a protective immune response in healthy children aged 1 to 11 years. About 300 children will receive either a full dose, a half dose, or a control vaccine. The study aims to find the right dose for this age group, potentially paving the way for a pediatric chikungunya vaccine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a live-attenuated chikungunya virus vaccine candidate called VLA1553, given as a single injection at full or half dose
What this could lead to: If successful, this could help protect children against chikungunya, a painful mosquito-borne viral disease, potentially leading to a pediatric vaccine.
What could go wrong: This is an early-phase trial, so the vaccine may not produce a strong enough immune response or could cause side effects. Results in children may differ from adults.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chikungunya

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA VIRUS INFECTION

Contacts and locations

Locations

Fundacion Dominicana de Perinatologia Fundacion Probebe

Santo Domingo, Gazcue, Dominican Republic
Instituto Dermatologico y Cirugia de la Piel "Dr Huberto Bogaert Diaz" IDCP

Santo Domingo, 10306, Dominican Republic
Inversiones en Investigacion Medica INVERIME

Tegucigalpa, Honduras

More trials for these conditions

Other studies related to the condition(s) this trial covers.